Clinical trials: Severe Asthma, active
Severe Asthma
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
The objective of this study is to assess the potential for GB-0895 to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers.
- Trial name
- NCT07276724
- Testing
- GB-0895
- Where
- 134 sites in United States, Brazil and 15 more
- Volunteers
- 786 people
- Sponsor
- Generate Biomedicines
Severe Asthma
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
The objective of this study is to assess the potential for GB-0895 to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers.
- Trial name
- NCT07359846
- Testing
- GB-0895
- Where
- 141 sites in United States, Argentina and 15 more
- Volunteers
- 786 people
- Sponsor
- Generate Biomedicines
Severe Asthma
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma..
- Trial name
- ARRIVAL (NCT06473779)
- Testing
- Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®)
- Where
- 70 sites in United States, Argentina and 10 more
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Moderate to Severe Asthma
PULmonary Stimulation for Asthma Relief
This study aims to assess the safety and efficacy of Pulmonary Neuromodulation in patients suffering from moderate to severe asthma
- Trial name
- PULSAR (NCT07709754)
- Testing
- Spinal Cord Stimulation
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Spiro Medical, Inc.
Chronic Obstructive Pulmonary Disease (COPD), Severe Asthma
COINCIDE: Cardineurovascular dIsease and Obstructive Airway Disease
Patients with chronic obstructive pulmonary disease (COPD) and severe asthma frequently present with cardiovascular comorbidities that contribute substantially to morbidity and mortality.
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Severe Asthma, Cardiovascular Diseases
- Trial name
- COINCIDE (NCT07856667)
- Testing
- Routine Clinical Care
- Volunteers
- 350 people
- Sponsor
- VASCage GmbH
Severe Asthma
Withdrawal of Dupilumab in Severe Asthma
Asthma management has been revolutionised by the development of biological therapies. Dupilumab is an anti-interleukin4 receptor marketed in 2020 for severe asthmatic patients with 2 exacerbations or more within the last 12…
- Trial name
- WIDUSA (NCT06818019)
- Testing
- Stopping dupilumab
- Where
- 29 sites in France
- Volunteers
- 205 people
- Sponsor
- University Hospital, Toulouse
Severe Asthma
Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)
This study is an observational multicenter cross-sectional study. Planned study population consists of 5 000 adult patients with uncontrolled SA receiving treatment according to standard of care (except biologics).
- Trial name
- CORSAR (NCT06472310)
- Where
- 40 sites in Russia
- Volunteers
- 5,000 people
- Sponsor
- AstraZeneca
Severe Asthma
Educational Needs of Patients With Severe Asthma on Targeted Immunotherapies
Severe asthma is a debilitating disease that affects every aspect of patients' lives: daily life, work, social life, family life, and marital life.
- Trial name
- BASIC (NCT07856407)
- Testing
- Initial assesment interwiew, Intake Interview with the Patient
- Volunteers
- 20 people
- Sponsor
- University Hospital, Angers
Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)
TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)
The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of Tezspire. 1. Development of related AEs 2.
- Trial name
- NCT05729711
- Where
- 33 sites in Japan
- Volunteers
- 416 people
- Sponsor
- AstraZeneca
Allergic Bronchopulmonary Aspergillosis, ABPA
Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma
An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis, ABPA, Severe Eosinophilic Asthma
- Trial name
- NCT07828327
- Testing
- Depemokimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Qianfoshan Hospital
Severe Eosinophilic Asthma
A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.
- Trial name
- ATHENA (NCT07214753)
- Testing
- benralizumab
- Where
- 28 sites in Italy
- Volunteers
- 335 people
- Sponsor
- AstraZeneca
Severe Asthma
Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)
A retrospective, observational, one arm, single country study, using the computerized database of Maccabi Health Services (MHS).
- Trial name
- SAIL-B (NCT07218172)
- Where
- Israel
- Volunteers
- 197 people
- Sponsor
- AstraZeneca
Eosinophilic Asthma, Severe Asthma
Fasenra: An Asthma Study
The goal of this observational study is to learn more about the effectiveness of benralizumab (Fasenra, 30 mg every 8 weeks) in maintaining asthma control in people with severe eosinophilic asthma.
- Conditions
- Eosinophilic Asthma, Severe Asthma, Severe Eosinophilic Asthma, Asthma
- Trial name
- NCT07654842
- Testing
- Budesonide-albuterol, Benralizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Endeavor Health
Moderate to Severe Asthma
CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma
Purpose: This study aims to improve asthma care by helping clinicians at community health centers prescribe a guideline-recommended treatment called SMART (Single Maintenance and Reliever Therapy).
- Trial name
- CHEST (NCT07241117)
- Testing
- Implementation bundle
- Where
- 7 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Washington University School of Medicine
Moderate to Severe Asthma
Phase II Trial of RC1416 Injection in Asthma
This study is a phase II study of RC1416 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of RC1416 in subjects with severe uncontrolled asthma.
- Trial name
- NCT07403487
- Testing
- RC1416
- Where
- 44 sites in China
- Volunteers
- 195 people
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
Severe Asthma
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while maintaining asthma symptom control.
- Trial name
- TAPER (NCT07363642)
- Testing
- Tezepelumab
- Where
- 75 sites in China
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Severe Asthma
Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in Russia
ELBRUS is a 12-month (52-week), multi-centre, prospective, non-comparative and non-interventional (observational), post-reimbursement real-world evidence study that will assess patient-reported outcomes after tezepelumab…
- Trial name
- ELBRUS (NCT06566885)
- Where
- 15 sites in Russia
- Volunteers
- 125 people
- Sponsor
- AstraZeneca
Asthma Atopic, Asthma Severe Persistent Uncontrolled
Expression of TSLP Isoforms in Asthma
Asthma is a heterogeneous disease characterized by chronic airway inflammation, leading to variable airflow obstruction, bronchial hyperresponsiveness, excessive mucus secretion, and, consequently, structural airway remodeling.
- Trial name
- NCT07786870
- Testing
- No Intervention: Observational Cohort
- Where
- Poland
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Moderate Asthma Exacerbation, Severe Asthma Exacerbation
Early High-flow Oxygen Therapy With nebuLized Beta-2-agonist Using a Vibrating Mesh for the Management of Moderate to Severe Asthma Exacerbation in the Emergency Department
Acute exacerbation of asthma represents an acute or sub-acute worsening in symptoms and lung function in patients with asthma. It is characterized by a progressive increase in symptoms of shortness of breath, cough, wheezing, or…
- Trial name
- EOLE (NCT05691218)
- Testing
- Standard Nebulization, A - Vibrating mesh nebulization, B - Vibrating mesh nebulisation and high-flow nasal cannula heated and humidified oxygen
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Poitiers University Hospital
Severe Asthma
Physical Activity Promotion and Clinical Remission in Severe Asthma
This study will investigate whether a structured physical activity promotion programme, delivered alongside standard treatment with tezepelumab, increases objectively measured physical activity and the proportion of adults with…
- Trial name
- NCT07735494
- Testing
- Physical activity promotion, Tezepelumab
- Where
- United Kingdom
- Volunteers
- 140 people
- Sponsor
- University of Leeds